ERBB2 and breast carcinoma: Furthermore, ADCs have shown great clinical activity in the treatment of other tumour types, especially in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, with the success of ado-trastuzumab emtansine [4] and trastuzumab-deruxtecan (DXd) treatments [5].